The CHMP, the European Medicines Agency’s human medicines committee, will this week decide whether a range of new medicines merit being approved.

BI’s global head of innovation Michel Pairet tells In Vivo that while unmet medical need is the pharma’s R&D priority, its main focus is bringing breakthrough therapy potential to patients, and it is taking aim at competitive spaces like metabolic health and cancer.

Boehringer Ingelheim's head of innovation Michel Pairet tells Scrip that while unmet medical need is the pharma’s R&D priority, its main focus is bringing breakthrough therapy potential to patients, and it is taking aim at competitive spaces like metabolic health and cancer.

With only weeks to go in 2022, the three major pharmas each had inked between 16 and 20 deals. Meanwhile, Pfizer has been less busy with 12 deals, but those include M&A totaling $18.2bn.